Back to Agenda
[V4-S6] Possibility of AI for Future New Drug Evaluation and Review Process
Session Chair(s)
Makoto Suzuki, PHD
Director, Medical Writing, MSD K.K., Japan
Share what next innovation technology is available in global drug development, such as AI translation in the medical field using multi-language speech translation technology of Ministry of Internal Affairs and Communications, and discuss shortening of approval review period using innovation such as AI.
Speaker(s)
Eiichiro Sumita, PHD
NICT Fellow, Associate Director General of ASTREC, National Institute of Information and Communications Technology (NICT), Japan
High Quality Automatic Translation By Using AI
Kazuya Obanayama
Digital Transformation Product Leader & PMO, Commercial Operations Management, Bayer Yakuhin, Ltd., Japan
Development and Influence of Digital Technonlogy
Megumi Sato
Sr, Specialist, Regulatory Operations, MSD K.K., Japan
Creation of Package Inserts Post-Marketing Materials Using XML
Have an account?